Back to Results

Aytu BioPharma Inc (AYTU)

Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics in the United States and select international markets. The company’s prescription portfolio includes products for attention deficit hyperactivity disorder, such as Adzenys XR-ODT, Cotempla XR-ODT, and Metadate CD. It also markets pediatric products including Karbinal ER, an extended-release carbinoxamine suspension for allergic conditions, along with Poly-Vi-Flor and Tri-Vi-Flor, fluoride-based multivitamin products for infants and children. Headquartered in Denver, Colorado, the company was previously known as Aytu BioScience, Inc. and adopted its current name in March 2021. The listed security is common stock on NASDAQ under the symbol AYTU.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-AYTU
$2.38
6.5% Upside
Fair
$9.50
326.0% Upside
Bargain
Fair
0.0%
0.6x
0.4x
23.935 M
19.031 M
50.0%
70.4%
-6.2
-4.8%
Valuation • Fair Value

Aytu BioPharma Inc (NASDAQ-AYTU) Fair Value by Valuation Model

Review the available estimates for Aytu BioPharma Inc (NASDAQ-AYTU), including Comps Fair Value.

Primary Valuation Read

Fair Value

$2.38

Estimated upside of 6.5% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

Comps Fair Value

$2.38

Comparable-company valuation reference.

Analyst Price Target

$9.50

Analysts imply upside of 326.0%.

How to read these valuation models

Use the 4 available valuation references for Aytu BioPharma Inc (NASDAQ-AYTU) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Aytu BioPharma Inc (NASDAQ-AYTU)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

56.599 M

Current operating scale indicator.

Revenue Forecast

53.4 M

Forward revenue estimate.

EBITDA

-2.625 M

Current operating profitability reference.

EBITDA Forecast

-7.9 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Aytu BioPharma Inc (NASDAQ-AYTU) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Aytu BioPharma Inc (NASDAQ-AYTU)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

3

Weak quality score that deserves closer review.

Beneish M-Score

-4.28

No elevated caution signal from this screen.

Altman Z-Score

-6.2

Lower score that deserves closer risk review.

FCF / Net Income

-4.8%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Aytu BioPharma Inc (NASDAQ-AYTU). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for Aytu BioPharma Inc (NASDAQ-AYTU)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for Aytu BioPharma Inc (NASDAQ-AYTU). No upcoming dividend amount or event date is currently available.

Stock Forecast • Technical Outlook

Aytu BioPharma Inc (NASDAQ-AYTU) Stock Forecast & Technical Outlook

Review Aytu BioPharma Inc (NASDAQ-AYTU) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Sell

The 15-minute technical read for Aytu BioPharma Inc (NASDAQ-AYTU) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Aytu BioPharma Inc (NASDAQ-AYTU) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Aytu BioPharma Inc (NASDAQ-AYTU) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Sell

The weekly technical read for Aytu BioPharma Inc (NASDAQ-AYTU) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Aytu BioPharma Inc (NASDAQ-AYTU) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Aytu BioPharma Inc (NASDAQ-AYTU)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Aytu BioPharma Inc (NASDAQ-AYTU) has a Strong Buy consensus, with 2 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 2
Hold 0
Sell 0
FAQ • Fast Investor Answers

Aytu BioPharma Inc (NASDAQ-AYTU) Stock FAQ

Data-supported answers about Aytu BioPharma Inc (NASDAQ-AYTU), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$2.38
Estimated upside 6.5%
Valuation Rating
Undervalued
Estimated upside of 6.5%
Analyst Target
$9.50
Implied upside 326.0%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Aytu BioPharma Inc (NASDAQ-AYTU) is $2.38. This implies an estimated upside of 6.5% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 6.5% versus the current market price.

The available analyst price target for Aytu BioPharma Inc (NASDAQ-AYTU) is $9.50. The analyst target implies estimated upside of 326.0%.

The current financial health read for Aytu BioPharma Inc (NASDAQ-AYTU) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The latest available data indicates no current dividend yield for Aytu BioPharma Inc (NASDAQ-AYTU).

The current market capitalization listed for Aytu BioPharma Inc is 23.935 M.

The current enterprise value listed for Aytu BioPharma Inc is 19.031 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Aytu BioPharma Inc is NASDAQ-AYTU, and the stock is listed on NASDAQ.

Aytu BioPharma Inc (NASDAQ-AYTU) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Aytu BioPharma Inc is 50.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Aytu BioPharma Inc is 70.4%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,043 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 648.7 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 372.3 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 269.8 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 175.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 159.2 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 127.2 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 102 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.536 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 46.053 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.268 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.639 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 30.107 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.733 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.616 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Overvalued Market Cap 12.702 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.456 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.639 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.564 B